Guidry Jacqueline, Brown Mariah, Medina Theresa
Division of Cutaneous Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Dermatol Online J. 2018 Dec 15;24(12):13030/qt2vj8b7cv.
Immune checkpoint modulators are becoming more prevalent in clinical use for the treatment of metastatic melanoma and other malignancies. These drugs, including programmed death 1 (PD-1) inhibitors, have a high incidence of immune adverse events, including cutaneous manifestations. Alopecia is a known side effect with these drugs, but previous reports describe chemotherapy-induced alopecia. We report a case of alopecia areata in a patient on monotherapy with pembrolizumab (PD-1 inhibitor). It is important for the dermatologist to recognize and appropriately treat to decrease morbidity for these patients.
免疫检查点调节剂在转移性黑色素瘤和其他恶性肿瘤的临床治疗中越来越普遍。这些药物，包括程序性死亡1（PD-1）抑制剂，免疫不良事件的发生率很高，包括皮肤表现。脱发是这些药物已知的副作用，但先前的报告描述的是化疗引起的脱发。我们报告了一例接受派姆单抗（PD-1抑制剂）单药治疗的斑秃患者。皮肤科医生认识到这一点并进行适当治疗以降低这些患者的发病率很重要。
